TICKERNERD
Menu
VNRXVNRXHealthcare · Medical Devices

VNRX Stock Forecast: VolitionRX Ltd. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$0.20
−2.35% on the day

The 5 Wall Street analysts covering VolitionRX Ltd. hold a median 12-month price target of $20 — +10140.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 31 Oct 2026 — in the lower half.

Market cap
$6.0M
Ticker Nerd rank
43/ 100
Median analyst target
$20
Analysts covering
5
Revenue$399K−2.0% y/y
Operating income−$4.2M
Net income−$7.3M
Free cash flow−$5.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+14.9%
1M
−24.9%
YTD
−96.2%
1Y
−97.8%
From 52W high
−97.8%
From 52W low
+14.9%
$0.17
$9.00
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VNRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores VolitionRX Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
43/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Accruals
77
Growth
76
Revisions
74
Volatility
40
Quality
19
Momentum
18
Value
18
Issuance
9

Size (94): Smaller than most of the companies we track.

Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

VNRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VNRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Jan 26Apr 26Jul 26Oct 26VNRXHigh $24Median $20Low $2

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $2Median $20High $24

The green dot is the last close — the median target sits +10140.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Apr 2026D. Boral CapitalDowngradeHold—
2 Apr 2026HC Wainwright & Co.MaintainsBuy—
31 Mar 2026D. Boral CapitalMaintainsBuy—
26 Mar 2026D. Boral CapitalMaintainsBuy—
18 Mar 2026D. Boral CapitalMaintainsBuy—
21 Jan 2026D. Boral CapitalMaintainsBuy—
9 Jan 2026D. Boral CapitalMaintainsBuy—
18 Dec 2025D. Boral CapitalMaintainsBuy—
4 Dec 2025D. Boral CapitalMaintainsBuy—
3 Dec 2025Maxim GroupDowngradeHold—
26 Nov 2025D. Boral CapitalMaintainsBuy—
21 Nov 2025Freedom BrokerMaintainsBuy—
17 Nov 2025D. Boral CapitalMaintainsBuy—
17 Nov 2025HC Wainwright & Co.MaintainsBuy—
30 Sept 2025HC Wainwright & Co.ReiteratesBuy—
29 Sept 2025D. Boral CapitalMaintainsBuy—
10 Sept 2025D. Boral CapitalMaintainsBuy—
15 Aug 2025D. Boral CapitalMaintainsBuy—
17 July 2025D. Boral CapitalMaintainsBuy—
9 July 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

VNRX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

VNRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, VolitionRX Ltd. returned −97.8% against +12.4% for the S&P 500, dividends included.

VNRX vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26VNRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VNRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

VolitionRX Ltd. (VNRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.0×

Cheaper than 77% of US stocks

Price / sales
2.4×

Cheaper than 47% of US stocks

Price / book
−0.1×

Cheaper than 93% of US stocks

EV / EBITDA
−0.5×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
−2.0%

Higher than 24% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−1042.5%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
65.6%

Higher than 94% of US stocks

Return on assets
−142.9%

Higher than 1% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

VolitionRX Ltd. (VNRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • VolitionRX Ltd. has a market value of $6.0M and an enterprise value of $9.9M.

  • Revenue in the twelve months to 30 June 2026: $2.5M. The latest quarter shrank 2.0% year on year.

  • Net income over the same four quarters: −$25.7M, a −1046.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$19.6M.

  • Shares outstanding: 12.0M.

  • Trailing P/E: −0.0×; forward P/E: −0.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • VolitionRX Ltd. employs 57 people — $43K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

VNRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
VNRXVolitionRX Ltd.$6.0M43
TNONTENON Medical, Inc.$5.5M51
BDMDBaird Medical Investment Holdings Ltd.$5.1M49
INBSIntelligent Bio Solutions, Inc.$5.8M16
NVNOenVVeno Medical Corp.$4.7M28
WOKWORK Medical Technology Group Ltd.$4.5M17
VVOSVivos Therapeutics, Inc.$3.8M37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own VolitionRX Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VNRX news & analysis

VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide

PRNewsWire · 27 Oct 2026positive

VolitionRx signed a non-binding LOI with Missionpharma to explore the potential development and worldwide launch of Volition’s prototype Lateral Flow Technology for NETosis.

Why it matters — The LOI signals a potential collaboration to develop and distribute Volition’s NETosis technology, though no binding commitment is described.

VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash

PRNewsWire · 27 Oct 2026positive

VolitionRx announced a $500,000 cash pre-payment on a convertible note, reducing its outstanding principal to $0.7 million. The company also said total debt reduction across both notes has exceeded $5.0 million since June 30, 2026, and agreed to pause conversion rights until January 2027, subject to a share-price condition, while deferring remaining 2026 monthly repayments.

Why it matters — The payment and revised note terms affect VNRX’s outstanding debt and the timing of potential share conversions and repayments.

VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France

PRNewsWire · 17 Sept 2026positive

VolitionRx shared further details and a video about the official launch of the Government-funded DETECSEPS Consortium in France, which focuses on early detection of sepsis. The announcement provides additional information about the project's initiation.

Why it matters — A VNRX watcher would care because this marks progress in Volition's participation in a government-funded consortium addressing sepsis early detection in France.

VolitionRx Participates in Launch of DETECSEPS Program in France

PRNewsWire · 17 Sept 2026positive

VolitionRx announced the official launch of the DETECSEPS program in France, a government-funded €6.3 million consortium focused on early sepsis detection. Volition's Nu.Q NETs assay was selected as the sole biomarker for France's real-world evaluation of early sepsis detection.

Why it matters — This selection positions Volition's Nu.Q NETs assay as the only biomarker in a French government-funded consortium, potentially broadening its clinical and commercial visibility in sepsis detection.

VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

PRNewsWire · 14 Sept 2026positive

VolitionRx Limited announced the full pre-payment in cash of the outstanding balance on its $7.5 million senior secured convertible promissory note issued to Lind Global Asset Management XII LLC, which was due May 20, 2027.

Why it matters — Fully paying off the convertible note in cash eliminates a potential conversion-related equity overhang on VNRX's shares.

FAQ

Frequently asked questions about VNRX stock

What is the VNRX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering VolitionRX Ltd. have a median 12-month price target of $20, with estimates ranging from $2 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VNRX stock a buy right now?

Of the 5 analysts covering VolitionRX Ltd., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks VolitionRX Ltd. 43 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VNRX?

As at 31 Oct 2026, VolitionRX Ltd. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

Will VNRX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +10140.7% from the last close, and Ticker Nerd's factor model ranks VolitionRX Ltd. 43 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VNRX stock forecast for 2030?

No analyst covering VolitionRX Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VNRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $24 over the next 12 months.

How has VNRX stock performed over the past year?

VolitionRX Ltd. returned -97.8% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does VolitionRX Ltd. do?

VolitionRx Limited is a multi-national epigenetics company focused on developing blood-based diagnostic tests for human and animal health. Its current product portfolio centers on the Nu.Q platform, which uses nucleosome-based biomarkers to help detect, monitor, and assess cancers and diseases associated with NETosis, including sepsis.

What is the latest news on VNRX?

The most recent item we track (PRNewsWire, 27 Oct 2026): "VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide". VolitionRx signed a non-binding LOI with Missionpharma to explore the potential development and worldwide launch of Volition’s prototype Lateral Flow Technology for NETosis.

Company

About VolitionRX Ltd.

VolitionRx Limited is a multi-national epigenetics company focused on developing blood-based diagnostic tests for human and animal health. Its current product portfolio centers on the Nu.Q platform, which uses nucleosome-based biomarkers to help detect, monitor, and assess cancers and diseases associated with NETosis, including sepsis. The company also offers veterinary applications such as Nu.Q Vet and research tools such as Nu.Q Discover, alongside technologies designed to support earlier disease detection and treatment monitoring. VolitionRx Limited serves healthcare and life sciences markets across the United States, Europe, and Asia from its headquarters in Henderson, Nevada.

CEO Mr. Cameron Reynolds MBA · 57 employees · United States · https://volition.com